Taddio A, Shennan A T, Stevens B, Leeder J S, Koren G
Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
J Pediatr. 1995 Dec;127(6):1002-5. doi: 10.1016/s0022-3476(95)70050-1.
The safety of lidocaine-prilocaine cream (EMLA) was evaluated in an open trial in 30 preterm neonates (mean gestational age, 32.8 weeks; birth weight, 1911 gm); 0.5 gm was applied to the heel for 1 hour. Mean baseline and follow-up (4, 8, or 12 hours after EMLA application) methemoglobin levels were not different, ranging from 1.15% to 1.45%, and from 1.13% to 1.49%, respectively.
在一项开放性试验中，对30名早产儿（平均胎龄32.8周；出生体重1911克）使用利多卡因-丙胺卡因乳膏（EMLA）进行安全性评估；将0.5克乳膏涂抹于足跟1小时。平均基线和随访（涂抹EMLA后4、8或12小时）时的高铁血红蛋白水平无差异，分别为1.15%至1.45%和1.13%至1.49%。
